Subscribe To
PGEN / Precigen, Inc. (PGEN) Q3 2022 Earnings Call Transcript
PGEN News
By Zacks Investment Research
September 5, 2023
Should You Buy Precigen, Inc. (PGEN) After Golden Cross?
Precigen, Inc. (PGEN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PGEN's 50-da more_horizontal
By Seeking Alpha
August 9, 2023
Precigen, Inc. (PGEN) Q2 2023 Earnings Call Transcript
Precigen, Inc. (NASDAQ:PGEN ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Steve Harasym - Vice President, Investor more_horizontal
By InvestorPlace
May 19, 2023
Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich
High-risk penny stocks have long tempted investors with the potential for significant returns. However, it is crucial to acknowledge the inherent risk more_horizontal
By Zacks Investment Research
March 14, 2023
Here's Why Precigen, Inc. (PGEN) Is a Great 'Buy the Bottom' Stock Now
Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to th more_horizontal
By PennyStocks
March 7, 2023
5 Penny Stocks To Buy According To Analysts, Targets Up To 952%
Penny stocks to buy according to analysts in 2023 The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% appeared first on Penny Sto more_horizontal
By The Motley Fool
February 16, 2023
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week. more_horizontal
By PennyStocks
February 6, 2023
3 Penny Stocks To Buy According To Insider Bets Up To $25 Million
Penny stocks to buy according to insider trades this quarter. The post 3 Penny Stocks To Buy According To Insider Bets Up To $25 Million appeared firs more_horizontal
By Zacks Investment Research
January 27, 2023
Precigen, Inc. (PGEN) Moves to Buy: Rationale Behind the Upgrade
Precigen, Inc. (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive more_horizontal